ImmunoEngineering and Cell Manufacturing: The Next Frontiers in Biomedical Engineering
Robert A. Milton Chair; Director, NSF ERC on Cell Manufacturing Technologies (CMaT); Director, Marcus Center for Cell-Therapy Characterization and Manufacturing (MC3M); Director, Center for ImmunoEngineering; The Wallace H. Coulter Dept. of Biomedical Engineering
Georgia Institute of Technology
March 29, 2018
Foege N130A, Wallace H. Coulter Seminar Room
Advanced biomanufacturing of therapeutic cells and engineering of the immune system in health and diseases are two emerging and intersecting areas in biomedical engineering. In this talk, I will provide a broad overview of this field, especially from a perspective of a biomaterials scientist. I will highlight our lab’s work on modulation of the immune system for vaccines and immunotherapies as well as our work on biomanufacturing of therapeutic immune cells. Specifically we will focus on how biophysical properties play a key role in modulating immune cell responses to vaccine adjuvants and how materials and bioengineering concepts can be used to manufacture therapeutic T and B cells. In addition I will discuss Georgia Tech’s effort on team science in both of these areas – especially focusing on a new NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT).
Dr. Krishnendu (Krish) Roy received his undergraduate degree from the Indian Institute of Technology (India) followed by his MS from Boston University and his PhD in Biomedical Engineering from Johns Hopkins University. After working for 2 years at Zycos Inc., a start-up biotechnology company, Dr. Roy left his industrial position to join the Biomedical Engineering Faculty at The University of Texas at Austin in 2002, where he was most recently Professor and Fellow of the Cockrell Chair in Engineering Excellence. He left UT-Austin in July of 2013 to move to Georgia Tech. where he is the Robert A. Milton Chaired Professor in Biomedical Engineering. At Georgia Tech, he also serves as the Director of the newly established NSF Engineering Research Center (ERC) for Cell Manufacturing Technologies (CMaT) and The Marcus Center for Cell-Therapy Characterization and Manufacturing (MC3M) – as well as the Director of the Center for ImmunoEngineering. He is also the Technical Lead of the NIST/AMTech National Cell Manufacturing Consortium (NCMC), a national public-private partnership, focused on addressing the challenges and solutions for large scale.